CAY10499: Precision Lipase Inhibition for Translational Lipidomics

Introduction

Dissecting lipid metabolism at molecular resolution is central to breakthroughs in metabolic disease, immunometabolism, and translational assay development. CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase (APExBIO, SKU B7841), has emerged as an advanced tool, enabling researchers to interrogate complex lipid signaling pathways with unprecedented specificity. While previous studies have highlighted its role in classic lipid metabolism assays or as an adjunct in immunometabolic workflows, this article uniquely focuses on CAY10499 as a linchpin for precision lipidomics and translational research—bridging cellular, molecular, and clinical applications with rigor and clarity.

Mechanism of Action: Dual Inhibition of HSL and MGL

CAY10499 is a crystalline small molecule engineered for selectivity against two pivotal enzymes in lipid homeostasis: hormone sensitive lipase (HSL) and monoglyceride lipase (MGL). HSL catalyzes the hydrolysis of tri-, di-, and monoacylglycerols, as well as cholesterol esters, mobilizing fatty acids for energy and participating in diverse physiological processes including steroidogenesis, spermatogenesis, and foam cell formation in atherosclerosis (product_spec). MGL, meanwhile, regulates the hydrolysis of monoglycerides such as 2-arachidonoylglycerol (2-AG), a critical endocannabinoid involved in neuronal signaling, inflammation, and energy balance.

CAY10499 demonstrates remarkable potency, inhibiting recombinant human HSL with an IC₅₀ of 90 nM and MGL-mediated hydrolysis of 4-nitrophenyl acetate (4-NPA) at 0.5 ± 0.03 μM (product_spec). Its action extends to full inhibition of fatty acid amide hydrolase (FAAH)-mediated [3H]-AEA hydrolysis (IC₅₀ = 76 nM), while showing minimal off-target affinity for CB1 and CB2 cannabinoid receptors. These properties make it an ideal reagent for dissecting fatty acid mobilization, lipid signaling, and metabolic flux without confounding receptor-mediated effects.

Reference Insight Extraction: EV-Transferred ACLY and Its Relevance to Lipidomics Assays

Recent advances in immunometabolism have spotlighted the role of extracellular vesicle (EV)-transferred ATP-citrate lyase (ACLY) in modulating monocyte differentiation toward tumor-associated macrophages (TAMs), fueling hepatocellular carcinoma (HCC) progression (paper). The referenced study demonstrates that tumor-derived EVs deliver ACLY to monocytes, triggering palmitate biosynthesis and S-palmitoylation of immune checkpoint proteins, which in turn reinforce the immunosuppressive tumor microenvironment. Notably, liposomal vesicles loaded with an ACLY inhibitor were sufficient to reverse TAM polarization and restrain HCC progression, underscoring the translational power of targeted metabolic modulation.

For translational lipidomics, this mechanistic insight is crucial: it exemplifies how manipulating specific lipid metabolic nodes—whether via ACLY or, by analogy, through HSL/MGL with CAY10499—can profoundly influence cell fate, immune function, and disease trajectory. Researchers leveraging CAY10499 for lipidomics can design assays that not only quantify enzymatic activity but also probe downstream consequences in immune cell differentiation, metabolic reprogramming, and therapeutic response.

Translational Lipidomics: Beyond Conventional Assays

Most existing articles on CAY10499 focus on its utility in lipid metabolism assay development or as an adjunct in immunometabolic research. This article goes further by mapping CAY10499's use to translational lipidomics—linking precise enzymatic inhibition to actionable insights in disease modeling, therapeutic screening, and high-content phenotyping.

For example, in studies of atherosclerosis or metabolic syndrome, CAY10499 enables researchers to decouple HSL- and MGL-dependent lipid signals from confounding pathways. This specificity is vital for mechanistic studies where multiple lipases may be co-expressed or co-regulated. Furthermore, by integrating CAY10499 into high-throughput lipidomics platforms, investigators can profile changes in free fatty acid pools, monoacylglycerols, and cholesterol esters with direct readouts of pathway perturbation—a leap beyond endpoint triglyceride assays (contrasting the focus on classic HSL/MGL inhibition workflows).

Comparative Analysis with Alternative Methods

Alternative strategies for lipid metabolism modulation often rely on genetic knockdown/knockout, broad-spectrum chemical inhibitors, or manipulation of upstream regulators (such as ACLY in the referenced EV study). CAY10499 offers several advantages:

• Temporal Control: Rapid, reversible inhibition allows kinetic assays and pulse-chase experiments.
• Selectivity: Minimal off-target action on cannabinoid receptors enhances interpretability (product_spec).
• Scalability: Solubility in DMSO and ethanol enables compatibility with cell-based, biochemical, and high-content screening assays.
• Workflow Integration: Can be combined with metabolic flux analysis, immunophenotyping, or transcriptomic profiling for multidimensional readouts.

In contrast, genetic approaches may introduce compensatory mechanisms or developmental alterations, while less selective inhibitors risk confounding readouts due to off-target effects. The referenced EV-ACLY study exemplifies how pathway-specific modulation can yield translationally actionable results—paralleling the benefits of CAY10499 for HSL/MGL-specific lipidomics.

Protocol Parameters

• assay | HSL inhibition IC₅₀ | 90 nM | cell-free and cell-based lipid hydrolysis assays | enables precise quantification of HSL activity | product_spec
• assay | MGL inhibition IC₅₀ (4-NPA hydrolysis) | 0.5 ± 0.03 μM | endpoint and kinetic monoacylglycerol hydrolysis assays | maximizes selectivity for MGL-mediated lipid turnover | product_spec
• assay | FAAH inhibition IC₅₀ ([3H]-AEA hydrolysis) | 76 nM | studies of endocannabinoid hydrolysis | expands utility in endocannabinoid research | product_spec
• formulation | DMSO solubility | ≥32.4 mg/mL | stock solution preparation for in vitro assays | assures high-concentration working stocks | product_spec
• formulation | ethanol solubility | ≥8.93 mg/mL | alternative for ethanol-compatible systems | broadens application range | product_spec
• formulation | water solubility | insoluble | avoid aqueous formulations | ensures experimental reproducibility | product_spec
• storage | temperature | −20°C | long-term stability | maintains compound integrity | product_spec
• storage | solution stability | short-term use recommended | daily/weekly working stocks | prevents degradation and loss of potency | product_spec

Advanced Applications: Disease Modeling and Immunometabolic Profiling

CAY10499's dual inhibition profile is exceptionally valuable in translational models where lipid metabolism intersects with disease phenotypes. For instance, in the context of cancer, immune dysfunction, or metabolic syndrome, dissecting HSL/MGL activity can clarify the contribution of lipid mobilization to cellular reprogramming, immune checkpoint expression, and disease progression. The referenced EV-ACLY study provides a paradigm: targeting a single metabolic node (ACLY) in immune cells modifies the tumor microenvironment and therapeutic response (paper). Analogously, CAY10499 can be used to:

• Investigate the impact of HSL/MGL inhibition on macrophage polarization and function in tumor models, complementing strategies targeting ACLY.
• Elucidate the role of fatty acid mobilization in steroidogenesis and reproductive biology, using CAY10499 as a selective enzyme inhibitor for fatty acid mobilization studies.
• Profile lipid signatures in foam cell formation and atherosclerosis, leveraging CAY10499 as a research tool for atherosclerosis to parse cell-type and pathway-specific contributions.

Unlike prior content which focuses primarily on assay development or lipid signaling mechanisms (see comparison), this article emphasizes translational endpoints, high-content analysis, and the integration of lipidomics with immune and disease phenotyping. APExBIO's quality assurance and detailed technical specifications support researchers seeking reproducibility in these advanced applications.

Why this cross-domain matters, maturity, and limitations

The intersection of lipid metabolism, immune cell fate, and disease progression is no longer a theoretical concern—it is central to next-generation diagnostics and therapeutics. The referenced study on EV-transferred ACLY reveals that targeting metabolic enzymes in immune cells can reprogram the tumor microenvironment and amplify immunotherapy efficacy. Applying this logic, selective HSL and MGL inhibition via CAY10499 may unlock parallel opportunities in disease modeling and translational research. However, direct clinical translation requires further preclinical validation, and in vivo pharmacokinetics of CAY10499 remain to be elucidated (workflow_recommendation).

Conclusion and Future Outlook

CAY10499 stands at the forefront of translational lipidomics, offering researchers a precise, scalable, and selective means of interrogating human hormone sensitive lipase and monoglyceride lipase function. By connecting rigorous enzymatic inhibition to downstream cellular and immunological outcomes, it supports advanced research in metabolic disease, immunometabolism, and disease modeling. The referenced EV-ACLY study underscores the potential impact of targeting metabolic enzymes within immune cells—CAY10499 provides a complementary approach for those studying HSL and MGL, with the promise to inform both discovery and translational science (paper).

Future research will benefit from integrating CAY10499 into high-content lipidomics, multiplexed immunophenotyping, and disease-relevant cell systems. As the field moves toward precision metabolism and immunotherapy, APExBIO’s CAY10499 enables the rigorous, pathway-specific interrogation required to drive true innovation in lipid biology.